Company intelligence / Profile preview

Cadence Neuroscience

Redmond, Washington, United Statescadenceneuro.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Cadence Neuroscience has developed an investigational implantable neuromodulation system that delivers targeted electrical stimulation to specific brain regions based on real-time detection of epileptogenic biomarkers. The technology aims to provide a new treatment option for patients with drug-resistant focal epilepsy and builds on pioneering research from Mayo Clinic. As of mid–2024, the core therapy remains under active clinical evaluation and has not yet reached commercial launch.

Therapeutic areas: Neurology
Modalities: DeviceNeuromodulation device therapyElectrical stimulation device (implantable)
Industry: Implantable Medical Devices

Partnerships

Mayo Clinic (technology origin/development partner)no major pharma/biotech commercialization partners disclosed

Beyond the preview

Go deeper on Cadence Neuroscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cadence Neuroscience.

Explore the full profile